The American Animal Hospital Association reported that Credelio has become the first veterinary drug to receive an Emergency Use Authorization from the U.S. Food and Drug Administration, a designation the agency has applied previously only to human medical products.

The AAHA news item, titled "First ever Emergency Use Authorization granted for veterinary drug Credelio (and what that means for veterinary medicine)," signals a procedural shift at the FDA Center for Veterinary Medicine and frames the action as a turning point for emergency preparedness across companion-animal, food-animal and public-health practice.

What is an Emergency Use Authorization?

An Emergency Use Authorization permits the FDA to make an unapproved medical product or an approved product available for an unapproved indication during a declared emergency when no adequate, approved alternative exists.

The mechanism operates under the Project BioShield Act of 2004 and has governed agency responses to the H1N1 influenza outbreak, the Ebola emergency and the COVID-19 pandemic, when vaccines, therapeutics and diagnostics reached the public through this pathway before formal approval.

Veterinary medicine has, until this action, lacked a designated federal emergency-use pathway of equivalent scale. Practitioners and producers instead rely on expanded-access and compassionate-use frameworks that operate case by case and cannot pre-position products for population-level deployment.

Why does a veterinary EUA matter?

A dedicated mechanism shortens the regulatory timeline for veterinary responses to emerging pathogens and removes the requirement for sequential New Animal Drug Application amendments. The result, in principle, is faster product access for the practitioners who need it and earlier containment of disease threats that would otherwise spread across herds, kennels or communities.

AAHA's framing of the Credelio action as a milestone for veterinary medicine reflects that shift. The association's news item, by titling the article "and what that means for veterinary medicine," positions the designation as a template for future emergency responses rather than a one-time event.

How does this change companion-animal practice?

For companion-animal veterinarians, a veterinary EUA pathway creates a defined route to products during canine influenza outbreaks, leptospirosis surges or vector-borne disease emergencies. The pathway bypasses the months-long label-extension process and allows practitioners to use authorized products under FDA CVM oversight.

Hospital accreditation standards under AAHA already incorporate emergency preparedness, and a designated veterinary pathway gives those standards a federal regulatory anchor for the first time.

What changes for food-animal veterinarians?

Food-animal veterinarians and producers work within a different regulatory frame. The FDA CVM and USDA APHIS divide jurisdiction over veterinary products by species and product class, and existing federal stockpiling authorities already cover some transboundary disease responses.

A veterinary EUA does not displace those frameworks. It adds a parallel mechanism that can be invoked when an emerging disease outpaces label-approved options and when a USDA APHIS response is not yet warranted or is in transition.

What is the public-health implication?

For public-health agencies, a veterinary EUA pathway extends the federal toolkit available during zoonotic emergencies. The One Health framework, formalized in federal planning since 2007, requires that animal and human health responses operate in coordination, and a designated veterinary mechanism strengthens that coordination by giving FDA CVM a defined emergency instrument.

Veterinary EUAs may also accelerate responses to zoonotic spillover events, where time from detection to deployment of countermeasures often determines the scale of human exposure.

What questions remain open?

The AAHA item does not specify the indication underlying the Credelio authorization, the date of the FDA CVM action, the declaration that triggered the designation, or the manufacturing commitments attached to the order. Practitioners, producers and One Health planners will look to FDA CVM for approval to clarify each of those points.

AAHA has indicated that it will publish further regulatory updates as federal agencies release guidance, and the Credelio designation will define the template for future veterinary emergency responses across the profession.